Fresenius Medical Care AG (FMS) Stock Price & How to Invest

Fresenius Medical Care treats end-stage kidney disease, the point at which a patient's kidneys have failed and dialysis or a transplant is the only option. It runs the largest network of outpatient dialysis clinics in the world, with the large majority of revenue coming from the United States, and it also manufactures the machines, dialyzers, bloodlines and water-treatment systems those clinics use, selling that equipment to third parties including its own competitors. Since a 2023 reorganisation the company reports in two segments: Care Delivery, the clinic network, and Care Enablement, the products business. Demand is close to non-discretionary, since a patient on hemodialysis typically needs three sessions a week indefinitely, but the price of each session in the US is set largely by Medicare rather than negotiated.

The investment picture as of August 2026 is a company priced for very little. Trailing revenue of roughly $19.4 billion supports a market capitalisation of roughly $12.7 billion, so the ADS changes hands at well under one times sales, reflecting flat volumes, heavy fixed costs and a decade of missed targets before the current turnaround. The second quarter of 2026 showed the shape management wants: revenue of about EUR 4.86 billion, up around 4 percent at constant currency, with operating income excluding special items up roughly 20 percent to about EUR 569 million and a margin near 11.7 percent. Management reaffirmed a 2026 outlook of broadly flat revenue alongside operating income growth. The problem sitting underneath that is US same-market treatment growth, which was negative in the quarter, so income is being manufactured from cost savings and mix rather than from more patients walking through the door.

The long-term structural worry is that GLP-1 drugs and SGLT2 inhibitors slow the progression of chronic kidney disease enough to shrink the future dialysis population, a thesis the company disputes on the grounds that better survival can also increase treatment years. Legal exposure is real and ongoing: the Department of Justice has intervened in a False Claims Act case alleging medically unnecessary vascular procedures at a Fresenius subsidiary, and the 2024 recall of 2008 series hemodialysis machines over compounds leaching from silicone tubing has drawn product-liability attention. Because the company reports in euros while earning most of its revenue in dollars, headline growth can diverge sharply from constant-currency growth, which is why the two figures differ by several points in most quarters. US clinic labour costs and nurse availability remain a persistent margin pressure, and leverage is meaningful for a business with this little top-line growth. As a German issuer, dividends are subject to German withholding tax before they reach a US ADS holder, and the company files as a foreign private issuer rather than on the domestic quarterly schedule.

7 analysts publish price targets on FMS, averaging $25.78 against a $23.77 price as of August 2026, or +8.5%. The published targets run from $17.37 to $38.22, a wide spread, and the ratings split 2 buy, 2 hold, 3 sell. Over the last six months there has been 1 raise and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full FMS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Fresenius Medical Care AG. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The FME25+ cost program. The transformation program is the main reason flat revenue is producing double-digit income growth, contributing about EUR 67 million of sustainable savings in the second quarter of 2026 alone. The most optimistic published target, $38.22, assumes this works close to its best case.

The case against. The long-term structural worry is that GLP-1 drugs and SGLT2 inhibitors slow the progression of chronic kidney disease enough to shrink the future dialysis population, a thesis the company disputes on the grounds that better survival can also increase treatment years. The most pessimistic target, $17.37, is roughly what FMS is worth if this bites instead.

Read the full bull and bear case on FMS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Fresenius Medical Care AG's investor relations page or your broker.

• Revenue (TTM): ~$19.4B (reported in euros)
• Market cap: ~$12.7B
• ADS price: ~$23.77
• Price / sales (TTM): ~0.65x
• Q2 2026 revenue: ~EUR 4.86B, ~+4% at constant currency
• Q2 2026 operating margin (ex special items): ~11.7%

A sub-one-times-sales multiple is unusual for a healthcare services business with near non-discretionary demand, and it prices in the flat volumes and reimbursement ceiling rather than any doubt about the need for the service. Because the company reports in euros and earns most of its revenue in dollars, the reported and constant-currency growth rates can differ by several percentage points, and screeners that convert figures at a spot rate will not match the company's own release. The valuation case rests on margin, since operating income is growing at a double-digit rate off a revenue line management itself guides to broadly flat.

Other names that sit close to FMS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get FMS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so FMS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where FMS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

FMS is an essential-care operator with capped pricing and stagnant volumes, where the current story is margin repair rather than growth.

Whether FMS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is FMS a buy or a sell?, and where the stock could go from here in the FMS stock forecast.

For income investors, whether FMS pays a dividend and how the payout looks is covered in does FMS pay a dividend? And to weigh FMS against a peer, read the full side-by-side comparisons: FMS vs DVA and FMS vs BAX.